Artesunate and cisplatin synergistically inhibit HNSCC cell growth and promote apoptosis with artesunate‑induced decreases in Rb and phosphorylated Rb levels-Reference-Cited by-同舟云学术

Artesunate and cisplatin synergistically inhibit HNSCC cell growth and promote apoptosis with artesunate‑induced decreases in Rb and phosphorylated Rb levels

Published:2023-06-19 Issue:2 Volume:50 Page:
ISSN:1021-335X
Container-title:Oncology Reports
language:
Short-container-title:Oncol Rep

Author:

Okamoto Hiroki¹,Yoshikawa Kazuhiro²,Shimada Akiko²,Sano Rui¹,Inukai Daisuke¹,Yamanaka Shunpei¹,Suzuki Susumu³,Ueda Ryuzo⁴,Ueda Hiromi¹,Fujimoto Yasushi¹,Ogawa Tetsuya¹

Affiliation:

1. Department of Otorhinolaryngology‑Head and Neck Surgery, Aichi Medical University School of Medicine, Nagakute, Aichi 480‑1195, Japan

2. Division of Biobank, Research Creation Support Center, Aichi Medical University, Nagakute, Aichi 480‑1195, Japan

3. Division of Research Creation, Research Creation Support Center, Aichi Medical University, Nagakute, Aichi 480‑1195, Japan

4. Department of Tumor Immunology, Aichi Medical University School of Medicine, Nagakute, Aichi 480‑1195, Japan

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology,General Medicine

Reference36 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: A randomised factorial phase III controlled trial;Morton;Cancer Chemother Pharmacol,1985

3. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck;Kish;Cancer,1984

4. Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck;Kish;Cancer Treat Rep,1982

5. Moderate renal dysfunction may not require a cisplatin dose reduction: A retrospective study of cancer patients with renal impairment;Ogawa;Int J Clin Oncol,2013

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis and biological evaluation of artesunate-Se derivatives as anticancer agents by inducing GPX4-mediated ferroptosis;Bioorganic Chemistry;2024-11

2. Artemisinin pre-treatment fore cisplatin dosage enhances high grade urothelial carcinoma treatment in male albino mice via reverse gene expression modulation of FGFR3, HRAS, P53 and KDM6A;BMC Cancer;2024-08-08

3. Targeting ferroptosis as a potential strategy to overcome the resistance of cisplatin in oral squamous cell carcinoma;Frontiers in Pharmacology;2024-04-22

4. Elucidating the role of FOS in modulating the immune microenvironment through fibroblast and myeloid cell regulation in locoregional recurrent HNSCC;Environmental Toxicology;2024-04-03

5. Antineoplastic Drug Synergy of Artesunate with Navitoclax in Models of High-Grade Serous Ovarian Cancer;Cancers;2024-03-28